At a glance
ClinicalIndex Comparison RecordN/ACompleted· 61 enrolled
Drug / intervention
TaurolockTMHep100 +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TaurolockTMHep100 Versus Saline 0.9% As Secondary Prevention of Catheter-related Bloodstream Infections (CRBSI); a Single Center, Double Blinded, Randomized, Controlled Study in Patients with Chronic Intestinal Failure Dependent on Home Parenteral Support (HPS)
In Brief
A clinical study evaluating TaurolockTMHep100 and 0.9 % saline for Catheter Related Blood Stream Infections and Intestinal Failure. Completed, enrolled 61 participants across 1 site.
Detailed Summary
The purpose of the trial is to compare two catheter lock solutions (active: 1.35% taurolidine and placebo: 0.9% saline), on the occurence of catheter related blood stream infection, in patients with intestinal failure and a central venous catheter for home parenteral support.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesDenmark
CollaboratorsTauroPharm
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartJun 2019
Primary CompletionFeb 2022
First PostedOct 2024
TodayJul 2026
First PostedOct 28, 2024
Enrollment StartJun 3, 2019
Primary CompletionFeb 28, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 1.7 years ago
Interventions
TaurolockTMHep100device
1.35% taurolidine containing catheter losk solution
0.9 % salinedevice
placebo